Pharmacoeconomic Guidelines: Cuba
Country/Region: Cuba
PE Guidelines
Methodological Guidelines for Health Economic Evaluation (2003)
PDF in Spanish
PDF in Spanish
PE Guidelines Source:
Cuba Ministry of Health
Information current as of Tuesday, January 21, 2020
Key Features
| Key Features | |
|---|---|
| Type of Guidelines | PE Guidelines |
| Title and year of the document | Methodological Guidelines for Health Economic Evaluation (2003) |
| Affiliation of authors | Ministry of Public Health, Nevalat Project, National School of Public Health MA in Economics |
| Purpose of the document | Provide recommendations for the conduction of studies to yield transparent, comparable, valid and credible results and facilitate researchers that have less experience in the subject with information on how to complete an economic evaluation. |
| Standard reporting format included | Yes |
| Disclosure | Yes |
| Target audience of funding/ author's interests | To those who conduct PE evaluations or evaluate PE studies (decision-makers) |
| Perspective | Society, government, patient perspective |
| Indication | Approved Indication |
| Target population | Clearly specified |
| Subgroup analysis | When necessary |
| Choice of comparator | Most prevalent treatment, most used treatment |
| Time horizon | Yes, recommendations given. |
| Assumptions required | Yes |
| Preferred analytical technique | CBA, CEA, CMA, CUA |
| Costs to be included | All relevant cost data should be clearly identified and explained in details. |
| Source of costs | Must be referenced and identified to relate to the relevance of costs data (i.e. databases). |
| Modeling | Yes |
| Systematic review of evidences | Yes, encourage meta-analysis |
| Preference for effectiveness over efficacy | Yes, effectiveness must be a part of every and all studies. |
| Preferred outcome measure | Effectiveness |
| Preferred method to derive utility | N/A |
| Equity issues stated | Yes |
| Discounting costs | Yes, use rates recommended by specific governement agencies. |
| Discounting outcomes | Yes, rates explained. |
| Sensitivity analysis-parameters and range | For all uncertain parameters, a plausible range must be defined for each parameter. |
| Sensitivity analysis-methods | One-way, multi-way, probabilistic analysis when adequate. |
| Presenting results | The results should be presented in a detailed, clear and transparent manner, so that if possible apply the findings within the country as well as in other countries. |
| Incremental analysis | Yes |
| Total costs vs effectiveness (cost/effectiveness ratio) | Yes |
| Portability of results (Generalizability) | Yes |
| Financial impact analysis | Yes |
| Mandatory or recommended or voluntary | Recommended |
Acknowledgement: